Lista de obras - Catherine Roche-Lestienne

A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.

artículo científico publicado en 2003

Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.

artículo científico publicado en 2016

Acute megakaryoblastic leukemia with der(7)t(5;7)(q11;p11 approximately p12) associated with Down syndrome: a fourth case report

artículo científico publicado en 2006

Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis

artículo científico publicado en 2007

CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder

artículo científico publicado en 2015

Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study

artículo científico publicado en 2011

Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia

artículo científico publicado en 2008

Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation

artículo científico publicado en 2007

Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.

artículo científico publicado en 2005

Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index.

artículo científico publicado en 2013

Correction: Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies.

artículo científico publicado en 2011

Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: a complex chromosomal rearrangement of underestimated frequency in disease progression?

artículo científico publicado en 2008

Cytogenetics in the management of "chronic myeloid leukemia": an update by the Groupe francophone de cytogénétique hématologique (GFCH).

artículo científico publicado en 2016

Detection of dicentric chromosome (9;20) in paediatric B-cell acute lymphoblastic leukaemia: prognostic significance.

artículo científico publicado en 2014

Diagnosis of intrachromosomal amplification of chromosome 21 (iAMP21) by molecular cytogenetics in pediatric acute lymphoblastic leukemia

artículo científico publicado en 2015

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

artículo científico publicado en 2018

Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia

scientific article published on 27 January 2020

Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.

artículo científico publicado en 2005

Familial myeloid malignancies with germline TET2 mutation

scientific article published on 11 December 2019

GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.

artículo científico publicado en 2011

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia.

artículo científico publicado en 2013

Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients

artículo científico publicado en 2010

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.

artículo científico publicado en 2009

Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition

artículo científico publicado en 2005

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

artículo científico publicado en 2010

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

artículo científico publicado en 2010

Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.

artículo científico publicado en 2017

Isolated tetrasomy 13: a fifth case report of a rare chromosome abnormality associated with poorly differentiated acute myeloid leukemia

scientific article published on 01 July 2006

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

artículo científico publicado en 2007

MED13L-related intellectual disability: involvement of missense variants and delineation of the phenotype

artículo científico publicado en 2018

MYD88 L265P mutation in Waldenstrom macroglobulinemia.

artículo científico publicado en 2013

Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy.

artículo científico publicado en 2008

Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.

artículo científico publicado en 2005

Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia

artículo científico publicado en 2011

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)

artículo científico publicado en 2006

Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.

artículo científico publicado en 2003

NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis

artículo científico publicado en 2016

Origin of resistance to Imatinib mesylate: lessons learned from this experience

artículo científico publicado en 2004

RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.

artículo científico publicado en 2008

Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies

artículo científico publicado en 2011

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

artículo científico publicado en 2002

Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft.

artículo científico publicado en 2004

TP53 mutation and its prognostic significance in Waldenstrom's Macroglobulinemia

artículo científico publicado en 2017

Targeting MYC in multiple myeloma

artículo científico publicado en 2018

Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia.

artículo científico publicado en 2016

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

artículo científico publicado en 2013

The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma

scientific article published on 24 October 2016

The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype

artículo científico publicado en 2014

The molecular anatomy of the FIP1L1-PDGFRA fusion gene.

artículo científico publicado en 2008

The prognosis impact of BCR-ABL P-loop mutations: worse or not worse?

scientific article published on 01 February 2007

WAGR syndrome and congenital hypothyroidism in a child with a Mosaic 11p13 deletion.

artículo científico publicado en 2017

[Cytogenetics and molecular genetics in myelofibrosis with myeloid metaplasia and polycythemia vera]

artículo científico publicado en 2006

Lista de obras de Catherine Roche-Lestienne

A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.

Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.

Acute megakaryoblastic leukemia with der(7)t(5;7)(q11;p11 approximately p12) associated with Down syndrome: a fourth case report

Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis

CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder

Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study

Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia

Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation

Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.

Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index.

Correction: Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies.

Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: a complex chromosomal rearrangement of underestimated frequency in disease progression?

Cytogenetics in the management of "chronic myeloid leukemia": an update by the Groupe francophone de cytogénétique hématologique (GFCH).

Detection of dicentric chromosome (9;20) in paediatric B-cell acute lymphoblastic leukaemia: prognostic significance.

Diagnosis of intrachromosomal amplification of chromosome 21 (iAMP21) by molecular cytogenetics in pediatric acute lymphoblastic leukemia

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia

Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.

Familial myeloid malignancies with germline TET2 mutation

GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia.

Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.

Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.

Isolated tetrasomy 13: a fifth case report of a rare chromosome abnormality associated with poorly differentiated acute myeloid leukemia

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

MED13L-related intellectual disability: involvement of missense variants and delineation of the phenotype

MYD88 L265P mutation in Waldenstrom macroglobulinemia.

Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy.

Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.

Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)

Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.

NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis

Origin of resistance to Imatinib mesylate: lessons learned from this experience

RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.

Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft.

TP53 mutation and its prognostic significance in Waldenstrom's Macroglobulinemia

Targeting MYC in multiple myeloma

Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia.

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma

The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype

The molecular anatomy of the FIP1L1-PDGFRA fusion gene.

The prognosis impact of BCR-ABL P-loop mutations: worse or not worse?

WAGR syndrome and congenital hypothyroidism in a child with a Mosaic 11p13 deletion.

[Cytogenetics and molecular genetics in myelofibrosis with myeloid metaplasia and polycythemia vera]